Gossamer Bio, Inc. (GOSS)
GOSS Stock Price Chart
Explore Gossamer Bio, Inc. interactive price chart. Choose custom timeframes to analyze GOSS price movements and trends.
GOSS Company Profile
Discover essential business fundamentals and corporate details for Gossamer Bio, Inc. (GOSS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Feb 2019
Employees
162.00
Website
https://www.gossamerbio.comCEO
Faheem Hasnain
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
GOSS Financial Timeline
Browse a chronological timeline of Gossamer Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.08, while revenue estimate is $4.30m.
Earnings released on 18 May 2026
EPS came in at -$0.20 falling short of the estimated -$0.17 by -17.65%, while revenue for the quarter reached $16.96m , beating expectations by +263.19%.
Earnings released on 17 Mar 2026
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%, while revenue for the quarter reached $13.80m , beating expectations by +83.44%.
Earnings released on 5 Nov 2025
EPS came in at -$0.21 falling short of the estimated -$0.19 by -10.53%, while revenue for the quarter reached $13.29m , beating expectations by +76.64%.
Earnings released on 5 Aug 2025
EPS came in at -$0.17 surpassing the estimated -$0.18 by +5.56%, while revenue for the quarter reached $11.49m , beating expectations by +112.41%.
Earnings released on 15 May 2025
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%, while revenue for the quarter reached $9.89m , beating expectations by +150.53%.
Earnings released on 13 Mar 2025
EPS came in at -$0.15 surpassing the estimated -$0.17 by +11.76%, while revenue for the quarter reached $9.38m , beating expectations by +37.24%.
Earnings released on 7 Nov 2024
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%, while revenue for the quarter reached $9.48m , beating expectations by +38.71%.
Earnings released on 12 Aug 2024
EPS came in at $0.22 falling short of the estimated $0.23 by -4.35%, while revenue for the quarter reached $95.84m , missing expectations by -16.14%.
Earnings released on 7 May 2024
EPS came in at -$0.19 matching the estimated -$0.19.
Earnings released on 5 Mar 2024
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%, while revenue for the quarter reached $6.78m .
Earnings released on 9 Nov 2023
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%.
Earnings released on 8 Aug 2023
EPS came in at -$0.45 surpassing the estimated -$0.49 by +8.16%.
Earnings released on 9 May 2023
EPS came in at -$0.52 surpassing the estimated -$0.55 by +5.45%.
Earnings released on 17 Mar 2023
EPS came in at -$0.59 surpassing the estimated -$0.62 by +4.84%.
Earnings released on 3 Nov 2022
EPS came in at -$0.65 surpassing the estimated -$0.66 by +1.52%.
Earnings released on 9 Aug 2022
EPS came in at -$0.74 falling short of the estimated -$0.67 by -10.45%.
Earnings released on 10 May 2022
EPS came in at -$0.76 surpassing the estimated -$0.77 by +1.30%.
Earnings released on 3 Mar 2022
EPS came in at -$0.74 matching the estimated -$0.74.
Earnings released on 8 Nov 2021
EPS came in at -$0.80 falling short of the estimated -$0.78 by -2.56%.
Earnings released on 9 Aug 2021
EPS came in at -$0.80 falling short of the estimated -$0.77 by -3.90%.
GOSS Stock Performance
Access detailed GOSS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
